Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-13
2007-02-13
Wilson, James O. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S429000, C548S571000
Reexamination Certificate
active
11268374
ABSTRACT:
Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
REFERENCES:
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5998428 (1999-12-01), Barnette et al.
patent: 6258833 (2001-07-01), Martins et al.
J.E. Schultz et al.,Naunyn-Schmiedeberg's Arch Pharmacol, 333, pp. 23-30 (1986).
Z. Ma et al.,Tetrahedron: Asymmetry, vol. 8, No. 6, pp. 883-887 (1997).
A. Robichaud et al.,Neuropharmacology, 38, pp. 289-297 (1999).
R.A. Allen et al.,Biochemical Pharmacology, vol. 57, pp. 1375-1382 (1999).
J. Beavo et al., “Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action,” Wiley and Sons, Chichester, pp. 3-14 (1990).
T.J. Torphy et al.,Drug News and Perspectives, 6, pp. 203-214 (1993).
M.A. Giembycz et al.,Clin. Exp. Allergy, 22, pp. 337-344 (1992).
J. Semmler et al.,Int. J. Immunopharmacol., 15, pp. 409-413 (1993).
K.L. Molnar-Kimber et al.,Mediators of Inflammation, 1, pp. 411-417 (1992).
M.W. Verghese et al.,J. Mol. Cell. Cardiiol., 21 (Suppl. 2),S61(1989).
C.P. Nielson et al.,J. Allergy Immunol., 86, pp. 801-808 (1990).
P.T. Peachell et al.,J. Immunol., 148, pp. 2503-2510 (1992).
G. Dent et al.,J. Pharmacol., 103, pp. 1339-1346 (1991).
S.A. Robicsek et al.,Biochem. Pharmacol., 42, pp. 869-877 (1991).
H.S. Dhillon et al.,J. Neurotrauma, 12, pp. 1035-1043 (1995).
N. Suttorp et al.,J. Clin. Invest., 91, pp. 1421-1428 (1993).
M.R. Bristow et al.,Circulation, 97, pp. 1340-1341 (1998).
G. Poli et al.,Proc. Natl. Acad. Sci. USA, 87, pp. 782-785 (1990).
P. Orosz et al.,J. Exp. Med., 177, pp. 1391-1398 (1993).
M. Mentz et al.,Blood, 88, pp. 2172-2182 (1996).
S. Takeda et al.,Kidney Int., 37, p. 362 (1990).
D. Chabardea et al.,Kidney Int., 35, p. 494 (1989).
C.D. Nicholson,Psychopharmacology, 101, p. 147 (1990).
F. Eckmann et al.,Curr. Ther. Res., 43, p. 291 (1988).
A. Klodzinska et al.,Neuropharmacology, 38, p. 1831 (1991).
H. Kato et al.,Eur. J. Pharmacol., 272, p. 107 (1995).
G. Gardos et al.,J. Clin. Pharmocol., 16, p. 304 (1976).
I. Shoulson et al.,Neurology, 25, p. 722 (1975).
T. Hayakawa et al.,Clin. Exp. Pharmacol. Physiol., 26, p. 421 (1999).
R.D. Porsolt et al.,Eur. J. Pharmacol., 47, p. 379 (1978).
R.D. Porsolt et al.,Eur. J. Pharmacol., 57, p. 431 (1979).
L. Steru,Psychopharmacology, 85, p. 376 (1985).
M. Takahashi,J. Neuroscience, 19, p. 610 (1999).
D. Pinsky et al.,J. Clin. Invest., 92, pp. 2994-3002 (1993).
Antidepressants: neurochemical, behavioral and clinical prospectives, Enna, Malick, and Richelson, eds., Raven Press, pp. 121-139 (1981).
H.J. Dyke et al.,Expert Opin. Investig. Drugs, 11(1), pp. 1-13 (2002).
Burgess Laurence Edward
Fowler Kerry W.
Gaudino John Joseph
Jones Zachary S.
Kesicki Edward A.
ICOS Corporation
Sackey Ebenezer
Wilson James O.
LandOfFree
Cyclic AMP-specific phosphodiesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic AMP-specific phosphodiesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic AMP-specific phosphodiesterase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3812346